Department of Allergy and Immunology, Walter Reed National Military Medical Center, Bethesda, Maryland.
Department of Research Programs, Walter Reed National Military Medical Center, Bethesda, Maryland.
Ann Allergy Asthma Immunol. 2020 Nov;125(5):577-580. doi: 10.1016/j.anai.2020.06.013. Epub 2020 Jun 13.
The first large-scale evaluation of prescribing patterns for imported fire ant (IFA) in a large US health care system was published by Haymore et al in 2009. In this first evaluation of prescriptions from 1990 to 2007, the most often prescribed maintenance IFA prescription was 0.5 mL of 1:200 wt/vol.
To provide an updated description of IFA prescribing patterns over the ensuing 11 years from same large health care system.
We reviewed 1349 new IFA prescriptions written from 2007 to 2018, from a large nationwide health care system, with primary end points being maintenance prescription strength and prescribing patterns.
In comparison to the data published by Haymore et al in 2009, which reported that 17% of the prescriptions were written for 0.5 mL of 1:100 wt/vol maintenance, we found that 69% (95% CI: 66.4%-71.4%) of IFA prescriptions written in the past 11 years were for the maintenance concentration of 0.5 mL of 1:100 wt/vol. We further studied the linear trend over time of percentage of prescriptions written for individual concentrations and observed that the percentage of 1:100 wt/vol prescriptions increased 3.5% yearly (R = 0.68, P < .001) from 2007 (40.0%, 95% CI: 24.6%-57.7%) to 2018 (84.4%, 95% CI: 77.4%-89.5%).
Our study shows significant improvement in the accuracy and precision of IFA immunotherapy dosing for patients with IFA hypersensitivity, with ascendancy of 0.5 mL 1:100 wt/vol as the predominant treatment dose. A total of 87% of patients within our study were treated within the parameter recommendations, a stark improvement from findings in the 2009 Haymore study.
海莫尔等人于 2009 年发表了美国大型医疗保健系统中首例关于红火蚁（IFA）处方模式的大规模评估。在对 1990 年至 2007 年的处方进行的首次评估中，最常开的维持性 IFA 处方是 0.5 毫升 1:200wt/vol。
提供同一大型医疗保健系统在随后 11 年中 IFA 处方模式的最新描述。
我们回顾了来自 2007 年至 2018 年的一家大型全国性医疗保健系统中开具的 1349 例新 IFA 处方，主要终点为维持处方强度和处方模式。
与海莫尔等人在 2009 年报告的 17%的处方开给 0.5 毫升 1:100wt/vol 维持液相比，我们发现过去 11 年中 69%（95%置信区间：66.4%-71.4%）的 IFA 处方为 0.5 毫升 1:100wt/vol 的维持浓度。我们进一步研究了各浓度处方的百分比随时间的线性趋势，发现 1:100wt/vol 处方的百分比每年增加 3.5%（R=0.68，P<.001），从 2007 年的 40.0%（95%置信区间：24.6%-57.7%）到 2018 年的 84.4%（95%置信区间：77.4%-89.5%）。
我们的研究表明，对 IFA 过敏患者的 IFA 免疫治疗剂量的准确性和精密度有了显著提高，0.5 毫升 1:100wt/vol 成为主要治疗剂量。我们研究中的 87%的患者接受了参数推荐范围内的治疗，与 2009 年海莫尔研究的发现相比有了显著改善。
